U.S. Pharmaceutical Logistics Market Size, Share, and Growth Forecast, 2026 - 2033

The U.S. pharmaceutical logistics market size is likely to be valued at US$78.7 billion in 2026, and is expected to reach US$100.8 billion by 2033, growing at a CAGR of 3.6% during the forecast period from 2026 to 2033, driven by the Drug Supply Chain Security Act (DSCSA), FDA Good Distribution Practice (GDP) regulations, the DEA’s controlled substance distribution licensing requirements, and the FDA’s 21 CFR Part 211 storage and distribution standards, which collectively mandate the highest supply chain compliance standards of any industry.

Driver – Drug Supply Chain Security Act (DSCSA) Full Enforcement Driving Compliance Infrastructure Investment

The U.S. Drug Supply Chain Security Act (DSCSA), enacted in 2013, entered full enforcement in November 2023 following the FDA's enforcement discretion extension announced in November 2022. The legislation mandates serialization, electronic track-and-trace capabilities, product verification, and interoperable product tracing throughout the U.S. pharmaceutical supply chain. It also requires manufacturers, wholesalers, repackagers, and dispensers to exchange electronic transaction information for every prescription drug transfer.

Compliance with the DSCSA has accelerated investments in advanced technologies and operational capabilities across the pharmaceutical logistics sector. Companies have deployed enterprise-wide serialization platforms, electronic product identifier (ePI) verification systems, and robust processes to identify and investigate suspect or illegitimate products. The integration with the FDA's interoperable electronic drug tracing framework has also become a critical compliance requirement. These regulatory mandates are driving sustained demand for third-party logistics (3PL) providers that deliver comprehensive, DSCSA-compliant logistics and traceability solutions.

Restraint – Pharmaceutical Wholesale Consolidation and Pricing Pressure on 3PL Margins

The U.S. pharmaceutical wholesale distribution market is highly consolidated, with three major companies, McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health, accounting for nearly 90% of prescription drug distribution nationwide. Their extensive market presence provides substantial bargaining power, enabling them to negotiate favorable agreements with pharmaceutical manufacturers and exert significant influence over distribution pricing. This competitive landscape places considerable pricing pressure on third-party logistics (3PL) providers.

Consequently, conventional prescription drug and over-the-counter (OTC) distribution operates with relatively thin margins. To differentiate themselves and maintain profitability, many specialized 3PL providers focus on high-value niche segments such as cold-chain logistics, specialty pharmaceuticals, and controlled substances. Companies including LifeScience Logistics, MD Logistics, and Langham Logistics have established expertise in these areas, where stringent regulatory requirements and limited competition support stronger market opportunities.

Opportunity – Clinical Trial Logistics Expansion and Decentralized Clinical Trial Supply Chain

The U.S. clinical trial logistics market is experiencing strong growth, driven by the FDA's accelerated approval pathways, which have increased the number of clinical-stage drug candidates entering development. The growing adoption of decentralized clinical trials (DCTs) has further boosted demand for specialized logistics services. In August 2023, the FDA issued guidance formally recognizing direct-to-patient delivery of investigational drugs as a standard approach within clinical trial supply chains.

Decentralized clinical trials require highly specialized logistics capabilities to ensure the safe and compliant distribution of investigational medicinal products (IMPs) directly from sponsor depots to patients' homes. Logistics providers must adhere to Good Manufacturing Practice (GMP) requirements, use temperature-controlled packaging tailored to each product's stability profile, maintain complete chain-of-custody documentation, and coordinate the return of unused or expired products. In addition, real-time shipment tracking and continuous temperature monitoring help support pharmacovigilance activities while enabling trial sponsors to verify product integrity throughout the distribution process.

Product Type Insights

Prescription drugs are expected to dominate the product type segment, accounting for approximately 39% of total market revenue in 2026. The segment comprises both branded and generic medicines distributed through major wholesale distributors such as McKesson, Cencora, and Cardinal Health, as well as retail pharmacies, mail-order pharmacy providers, and hospital pharmacy networks. Owing to the large volume of prescription drug shipments, this segment represents the largest share of freight movement in the U.S. pharmaceutical logistics market.

Cell and gene therapies are projected to be the fastest-growing product type during the forecast period. Their autologous manufacturing process requires highly specialized cryogenic logistics to preserve product integrity throughout the supply chain. Logistics providers are responsible for transporting patient apheresis samples from healthcare facilities to manufacturing sites and delivering finished CAR-T cell and gene therapy products back to treatment centers for scheduled infusions. Given their complex handling requirements and high logistics cost per patient, these therapies are creating a rapidly expanding, high-value specialty logistics market. In response, companies such as MD Logistics and Crown LSP Group are increasing investments to strengthen their capabilities in this segment.

Service Type Insights

Transportation is expected to lead the service type segment, accounting for approximately 52% of total market revenue in 2026. The segment encompasses FDA- and DEA-regulated interstate truckload and less-than-truckload (LTL) freight services, temperature-controlled air transportation for biologics and clinical trial materials, last-mile delivery to pharmacies and patients, and specialized cryogenic transportation for cell and gene therapies. The increasing demand for secure, compliant, and temperature-sensitive pharmaceutical distribution continues to drive the growth of this segment.

Value-added services are projected to be the fastest-growing service segment over the forecast period, supported by the rising trend of pharmaceutical companies outsourcing complex supply chain operations. Logistics providers are expanding their offerings to include DSCSA serialization compliance, kitting, co-packaging for specialty pharmacies, returns management, pharmaceutical waste disposal, and direct-to-patient specialty pharmacy fulfillment. These advanced capabilities are enabling logistics companies to evolve from traditional freight carriers into strategic, end-to-end pharmaceutical supply chain partners.

Mode of Operation Insights

Non-cold-chain logistics are expected to dominate the market, commanding over 61% of total revenue in 2026. Growth reflects the large volume of ambient-stable prescription and OTC medicines. These products are distributed through conventional warehouse and transportation networks. They require temperature-controlled environments but do not need refrigeration.

Cold-chain logistics are likely to be the fastest-growing segment. Growth is driven by the increasing use of biologics and biosimilars. Expanding COVID-19 and RSV vaccine storage and distribution also support demand. The launch of cell and gene therapies requiring ultra-cold storage is another major driver. Companies such as LifeScience Logistics, Langham Logistics, and KRC Logistics are expanding investments in dedicated cryogenic logistics networks.

The U.S. pharmaceutical logistics market is characterized by intense competition, with the presence of global logistics companies offering dedicated life sciences solutions alongside specialized pharmaceutical third-party logistics (3PL) providers equipped with Good Distribution Practice (GDP)-compliant infrastructure. Many niche providers have established expertise in high-value segments such as cold-chain logistics, clinical trial supply chains, and cell and gene therapy transportation.

Kuehne + Nagel is among the leading providers in the pharmaceutical logistics market. Through its KN PharmaChain platform, the company offers temperature-controlled air and ocean freight services, GDP-compliant warehousing, validated cold-chain packaging solutions, and clinical trial logistics. Its U.S. operations support both domestic pharmaceutical distribution and international life sciences supply chains.

Another prominent participant is DSV, which delivers specialized pharmaceutical logistics services through its Air & Sea and Road business divisions. The company provides temperature-controlled transportation, compliant warehousing, and integrated supply chain solutions, leveraging its extensive global network to support both domestic pharmaceutical distribution within the U.S. and international logistics operations.

Key Industry Developments:

• In November 2025, United Parcel Service completed its acquisition of Andlauer Healthcare Group (AHG) for about USD 1.6 billion, significantly enhancing its cold chain and pharmaceutical logistics capabilities across North America and globally.
• In October 2025, FedEx expanded its healthcare logistics footprint, adding specialized healthcare logistics services (e.g., temperature-controlled solutions, advanced tracking, value-added fulfillment) and investing in life science centers globally, including in the United States, aimed at biologics, vaccines, and clinical samples.